Journal of Hepatology最新文献

{"title":"In memoriam: Harry Dalton (17th December 1958-19th March 2024)","authors":"Eleanor Barnes, Heiner Wedemeyer","doi":"10.1016/j.jhep.2025.03.016","DOIUrl":"https://doi.org/10.1016/j.jhep.2025.03.016","url":null,"abstract":"Hepatitis E virus (HEV) infection is a hepatotropic infection of global importance, an international scourge, and a cause of significant death and morbidity. It causes endemic outbreaks typically, and particularly in Asia, which are associated with faecal-oral/water-borne transmission and a high mortality in vulnerable groups, including pregnant women. In Western countries, sporadic HEV infections cause severe jaundice, liver decompensation and inflammation, typically in older men. HEV has also been shown to cause persistent infection in immune compromised people leading to liver fibrosis and cirrhosis, and severe neurological disease. Harry Dalton, a UK-based clinician scientist dedicated his academic career to the study of HEV infection and is internationally renowned for his discoveries on the pathogenesis of HEV. His career path was both unconventional and remarkable and he touched many of us with his inspirational work and determination. In this memoriam we aim to highlight his extraordinary contributions, drive, and dedication to hepatology, that may serve as an inspiration to others. Harry constantly challenged the existing “dogmas” opening our eyes to new possibilities and theories – it was this open mindedness, along with his ability to enthuse others, establishing life-long collaborations, that enabled his discoveries.","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"30 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144066519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"JHEP at a glance (June 2025)","authors":"","doi":"10.1016/S0168-8278(25)00264-8","DOIUrl":"10.1016/S0168-8278(25)00264-8","url":null,"abstract":"","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"82 6","pages":"Pages e275-e285"},"PeriodicalIF":26.8,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143979772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study","authors":"Do-Youn Oh, Aiwu Ruth He, Shukui Qin, Li-Tzong Chen, Takuji Okusaka, Jin Won Kim, Thatthan Suksombooncharoen, Myung Ah Lee, Masayuki Kitano, Howard A. Burris, Mohamed Bouattour, Suebpong Tanasanvimon, Renata Zaucha, Antonio Avallone, Juan Cundom, Aleksandra Kuzko, Julie Wang, Ioannis Xynos, Arndt Vogel, Juan W. Valle","doi":"10.1016/j.jhep.2025.05.003","DOIUrl":"https://doi.org/10.1016/j.jhep.2025.05.003","url":null,"abstract":"<h3>Background</h3>At the TOPAZ-1 (NCT03875235) primary analysis, durvalumab plus gemcitabine and cisplatin (GemCis) significantly improved overall survival (OS) in advanced biliary tract cancer (aBTC). We report updated exploratory analyses of OS and safety, characterisation of extended long-term survivors (eLTS), and subsequent anticancer therapy (SAT) use.<h3>Methods</h3>Participants with aBTC received durvalumab+GemCis or placebo+GemCis every 3 weeks (≤8 cycles), then durvalumab or placebo monotherapy every 4 weeks until progressive disease or other discontinuation criteria were met. OS and serious adverse events (SAEs) were assessed in the full analysis and safety analysis sets (FAS/SAS), respectively. eLTS outcomes were assessed (FAS participants alive ≥30 months after randomisation).<h3>Results</h3>685 participants were randomised: durvalumab+GemCis (n = 341); placebo+GemCis (n = 344). After a median 41.3 (95% confidence interval [CI] 39.3–44.1) months’ follow-up in all participants, median OS (95% CI) for durvalumab+GemCis versus placebo+GemCis was 12.9 (11.6–14.1) versus 11.3 (10.1–12.5) months (hazard ratio, 0.74 [95% CI 0.63–0.87]); 36-month OS rate was 14.6% versus 6.9%, respectively. In participants who achieved disease control (566/685; 82.6%), the 36-month OS rate was higher for durvalumab+GemCis (17.0%) versus placebo+GemCis (7.6%). Overall, 12.8% were eLTS, with more eLTS in the durvalumab+GemCis (17.0%) versus placebo+GemCis (8.7%) arms; eLTS included all clinically relevant subgroups. Durvalumab+GemCis improved OS regardless of SAT use. In eLTS, SAEs were comparable between arms and less frequent than in the full SAS.<h3>Conclusions</h3>Survival benefit and manageable safety continued with durvalumab+GemCis versus placebo+GemCis approximately 3 years after the last participant was randomised. All clinically relevant subgroups were represented in eLTS, supporting standard-of-care status for durvalumab+GemCis in aBTC.<h3>Lay summary</h3>The TOPAZ-1 study found that treatment with durvalumab plus gemcitabine and cisplatin (chemotherapy, also known as GemCis), helped people with advanced biliary tract cancer (BTC) to live longer on average than those treated with a placebo plus GemCis. The latest results from TOPAZ-1 showed that these benefits continued for over 3 years in participants treated with durvalumab plus GemCis and side effects continued to be manageable. At an updated analysis, carried out 3 years after the last participant started the study, twice as many participants treated with durvalumab plus GemCis were alive compared to those treated with placebo plus GemCis. Results also showed that the positive effect of durvalumab plus GemCis compared with placebo plus GemCis was not affected by the use of other therapies some participants received after they finished the study treatment. These results continue to support durvalumab plus GemCis as a standard first-line treatment for people with advanced BTC.<h3>Clinical trial r","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"29 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144066583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From the Editor’s Desk...","authors":"Philip Newsome, Frank Tacke, Heiner Wedemeyer, Lorenza Rimassa, Annalisa Berzigotti, Tom H. Karlsen, Vlad Ratziu","doi":"10.1016/j.jhep.2025.03.012","DOIUrl":"10.1016/j.jhep.2025.03.012","url":null,"abstract":"","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"82 6","pages":"Pages 947-949"},"PeriodicalIF":26.8,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143979777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Discover the EASL DeepDive, a free educational webinar series offering an in-depth exploration of specific topics in hepatology and liver research","authors":"","doi":"10.1016/S0168-8278(25)00258-2","DOIUrl":"10.1016/S0168-8278(25)00258-2","url":null,"abstract":"","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"82 6","pages":"Page iv"},"PeriodicalIF":26.8,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143979769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Join the community and become an EASL member today!","authors":"","doi":"10.1016/S0168-8278(25)00257-0","DOIUrl":"10.1016/S0168-8278(25)00257-0","url":null,"abstract":"","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"82 6","pages":"Page iii"},"PeriodicalIF":26.8,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143979770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The EASL Guidelines app is your indispensable mobile companion for accessing comprehensive and up-to-date clinical practice guidelines in hepatology. Download it now!","authors":"","doi":"10.1016/S0168-8278(25)00256-9","DOIUrl":"10.1016/S0168-8278(25)00256-9","url":null,"abstract":"","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"82 6","pages":"Page ii"},"PeriodicalIF":26.8,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143979768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"DECISION is an international, EU-funded research project on decompensated cirrhosis to identify new combinatorial therapies based on systems approaches. Discover the project!","authors":"","doi":"10.1016/S0168-8278(25)00259-4","DOIUrl":"10.1016/S0168-8278(25)00259-4","url":null,"abstract":"","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"82 6","pages":"Page v"},"PeriodicalIF":26.8,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143979771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Establishing five-year overall survival as a new standard for trials in advanced HCC","authors":"Pierre Nahon","doi":"10.1016/j.jhep.2025.05.001","DOIUrl":"https://doi.org/10.1016/j.jhep.2025.05.001","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Disclosures</h2>Pr Nahon has received honoraria from and/or consults for AstraZeneca, Bristol-Myers Squibb, Eisai, and Roche. He received research grants from AstraZeneca, Bristol-Myers Squibb and Eisai.</section></section><section><section><h2>Grant Support</h2>Pierre Nahon’s research is funded in part by the European Union (GENIAL, Grant agreement ID: 101096312), French Agence Nationale de la Recherche (France 2030 DELIVER ANR-21-RHUS-0001) and by France 2030 RHU LIVER-TRACK (ANR-23-RHUS-0014).</section></section><section><section><h2>Declaration of Competing Interest</h2>none to declare</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"55 29 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143940273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Why One PEth Result Cannot Redraw the MASLD/ALD Boundary: A Single-Snapshot Misclassification","authors":"Tao Zhang","doi":"10.1016/j.jhep.2025.05.002","DOIUrl":"https://doi.org/10.1016/j.jhep.2025.05.002","url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Authors' contributions</h2>Tao Zhang is the only author of this letter and made all contributions.</section></section><section><section><h2>Financial support</h2>This letter receives no financial support.</section></section><section><section><h2>Declaration of Competing Interest</h2>There is no conflict of interest.Please refer to the accompanying ICMJE disclosure forms for further details.</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"26 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143940272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}